News in the Life Sciences Industry

SINGAPORE, Nov. 11, 2020 /PRNewswire/ -- Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA) Singapore on 8th May 2020, CE-IVD marking in... Read more ››

BEIJING, Nov. 10, 2020 /PRNewswire/ -- Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica... Read more ››

SEONGNAM, South Korea, Nov. 9, 2020 /PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (288330 KQ) reported to the Korea Stock Exchange that the Company and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into in July 2019... Read more ››

LEIDEN, The Netherlands, Nov. 9, 2020 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announces the appointment of Jeroen Wakkerman as Chief Financial Officer (CFO), with effect from 16 November 2020.

SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- On November 6, Merck, a leading science and technology company, announced the signing of a Letter of Intent with Donghao Lansheng... Read more ››

SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- On November 7, Merck, a leading science and technology company, and Transcenta, a global biotherapeutics company, announced a strategic technology... Read more ››

SHANGHAI, Nov. 6, 2020 /PRNewswire/ -- Johnson & Johnson Innovation, division of Johnson & Johnson (China) Investment Limited, announced today three new collaborations with strategic partners in China at the third China International Import Expo (CIIE) in Shanghai. These latest collaborations,... Read more ››

BRUSSELS, Nov. 5, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data on its TNF inhibitor, CIMZIA(® )(certolizumab pegol), and investigational IL-17A and IL-17F inhibitor, bimekizumab. Data are being presented at the American College of Rheumatology... Read more ››